These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2932585)

  • 21. Anti-tumor effects of the oral administration of the streptococcal preparation OK-432 (PICIBANIL)--the inhibition of carcinogenesis and growth in rats with ENNG-induced gastrointestinal tumors.
    Takeshita M; Makita F; Takeyoshi I; Ishikawa H; Nakamura S; Owada S; Miyamoto Y; Izuo M; Kurashige S
    Jpn J Surg; 1990 May; 20(3):316-26. PubMed ID: 2359208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction of suppressor cells in cancer patients treated with OK-432 immunotherapy.
    Uchida A; Hoshino T
    Int J Cancer; 1980 Oct; 26(4):401-4. PubMed ID: 6454666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [TNF induction in the serum and ascites of a gastric cancer patient treated with OK-432].
    Neda H; Watanabe N; Sone H; Yamauchi N; Niitsu Y; Urushizaki I
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):593-7. PubMed ID: 3954382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Administration of hemolytic streptococcus preparation OK-432 on recurrent gastric carcinoma].
    Hanaue H; Kurosawa T; Kitano Y; Miyagawa S; Nemoto A; Yamato H; Asagoe T; Shikata J
    Nihon Gan Chiryo Gakkai Shi; 1987 Aug; 22(7):1367-72. PubMed ID: 3501455
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of cancer ascites by intraperitoneal administration of a streptococcal preparation OK-432 with fresh human complement--role of complement-derived chemotactic factor to neutrophils.
    Kondo M; Kato H; Yoshikawa T; Sugino S
    Int J Immunopharmacol; 1986; 8(7):715-21. PubMed ID: 3536766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of suppressor cell activities of human peripheral blood lymphocytes by a streptococcal preparation, OK-432.
    Toge T; Yamada H; Aratani K; Yamaguchi M; Fujita T; Yanagawa E; Hattori T
    Int J Immunopharmacol; 1987; 9(8):875-9. PubMed ID: 2892805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Augmentation of cytotoxicity of regional lymph node lymphocytes of gastric cancer after intratumoral injection of OK-432].
    Kobayashi G
    Nihon Geka Gakkai Zasshi; 1990 Jan; 91(1):68-76. PubMed ID: 2314383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effect of peri-operatively administrated OK-432 on immunopotency in primary liver cancer--immunological and histological study in cases receiving intrahepatic arterial administration].
    Taniwaki S
    Nihon Shokakibyo Gakkai Zasshi; 1990 Apr; 87(4):1020-7. PubMed ID: 2376898
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Postoperative cell-mediated immunity in gastric cancer patients--with special reference to the effects of immunotherapy].
    Sekizuka H; Noro K; Haruyama S; Kiribuchi Y; Hayashi F
    Gan No Rinsho; 1985 Sep; 31(11):1381-6. PubMed ID: 3877822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of immunotherapeutic activity of OK-432 in the treatment of peritoneal carcinomatosis.
    Fukui H; Reynolds CW; Lenz B; Schneider M; Talmadge JE
    Cancer Immunol Immunother; 1989; 29(1):1-6. PubMed ID: 2784999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A case of unresectable advanced gastric cancer with effective treatment by local administration of OK-432 on operation].
    Kodama M; Taniguchi T; Furukawa H; Takahashi T; Hara T
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2301-3. PubMed ID: 2735772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2: induction of autologous tumor-reactive CD4+ Th1 killer lymphocytes.
    Yamaguchi Y; Miyahara E; Ohshita A; Kawabuchi Y; Ohta K; Shimizu K; Minami K; Hihara J; Sawamura A; Toge T
    Br J Cancer; 2003 Nov; 89(10):1876-84. PubMed ID: 14612896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Subsets of peripheral blood lymphocytes and tumor infiltrating lymphocytes in cancer patients received chemotherapy].
    Mitachi Y; Murakawa Y; Okuno M; Kambe M; Kanamaru R; Takahasi H; Wakui A
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):482-8. PubMed ID: 2138871
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of endoscopical administration of OK-432 in 4 patients with advanced esophageal or gastric cancer].
    Satomi T; Inoue S; Fujita T; Ogawa S; Honda H; Hayashi M
    Gan No Rinsho; 1989 Mar; 35(4):512-5. PubMed ID: 2541269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The endoscopic intratumor administration of OK-432 in gastric cancer unsuitable for surgery.
    Nakazawa S; Yoshino J; Kijima Y; Yasumasa N; Ohhashi S; Mizutani K
    Endoscopy; 1989 Jul; 21(4):168-71. PubMed ID: 2776702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Local immunotherapy for cancer].
    Hattori T; Niimoto M; Toge T; Hamamoto S; Seto Y; Kameda A; Tomoda S
    Nihon Geka Gakkai Zasshi; 1984 Sep; 85(9):1157-61. PubMed ID: 6503978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intractable massive ascites following radical gastrectomy, treatment with local intraperitoneal administration of OK-432 using a unified CT and fluoroscopy system.
    Inaba Y; Arai Y; Matsueda K; Aramaki T; Kodera Y
    Australas Radiol; 2003 Dec; 47(4):465-7. PubMed ID: 14641206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Induction of LAK cells in peritoneal cavity of mice after ip injection of OK-432 and antitumor effect of these LAK cells].
    Ishida N; Saito M; Nanjo M
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2681-90. PubMed ID: 6508321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual effects of OK-432 on mitogenic response of splenocytes to concanavalin A.
    Tomioka H; Saito H; Nagashima K
    Microbiol Immunol; 1985; 29(4):349-58. PubMed ID: 3160916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A double blind study of the evaluation of the optimal dose and its frequency in oral administration of OK-432 (Picibanil) by immunological parameters (the 1st report)].
    Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S
    Nihon Gan Chiryo Gakkai Shi; 1990 Apr; 25(4):799-811. PubMed ID: 2196311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.